CG Results Healthcare has advised GSK on the divestment of its Poznań, Poland manufacturing site to Delpharm

  • Service: Divestments
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech, CROs & CMOs
  • Engagement Type: Sell Side
Oct 2020
has divested its Poznań, Poland manufacturing site to

GSK and Delpharm have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland. Subject to the appropriate regulatory clearances, the transaction will see the ownership of GSK’s Poznań manufacturing site, including all facilities and around 700 manufacturing employees, transfer over to Delpharm. Delpharm will continue to manufacture, under contract, the existing GSK product line for a minimum of five years, while GSK will remain the owner and marketing authorization holder of these products.

Delpharm, headquartered in France, is a global contract development and manufacturing organization (CDMO). The company has been providing development services for more than 30 years, and serves 120 markets.

“We have a talented and dedicated team whose high standards have ensured that the Poznań manufacturing site has been performing strongly,” said Kamilla Niedzielska, Poznań site director, GSK. “Our priority is to support them through the transition and consult with them along the way, along with Delpharm. In the meantime, we remain wholly committed to maintaining operations and delivering continuity of supply for our patients and consumers.”

Delpharm said it is committed to expanding its worldwide supply and the Poznań manufacturing site, with its competitive cost base, high quality production, continuous improvement mindset and diverse dose forms, has an important role to play.

Sébastien Aguettant, chief executive officer, Delpharm, said, “Further to our existing businesses with GSK Consumer Healthcare and Vaccines, we are delighted to expand our partnership with GSK Phama with the acquisition of the Poznan sites which is our first step in Central and Eastern Europe.”

GSK has been present in Poland for over 40 years, employing over 2,400 people in the country.

Poznań remains a key strategic location for GSK which has hired over 270 people during the past twelve months at its Europe Finance Hub, established in the city in 2019. The Business Service Center in Poznań was set up in 2005 and is the biggest GSK unit in Poland, made up of 700 specialists, both full time and contract workers.

Sector Related Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company